Neurology
Latest News
NeurologyLive® Brain Games: September 7, 2025
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical...
Collaborative Strategies to Enhance Care and Data Sharing in LGS
WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors. Lennox-Gastaut syndrome (LGS) is a rare epilepsy syndrome that typically b...
AP-101 Meets Primary End Point in Phase 2 Study of SOD1 ALS
According to a new announcement, AL-S Pharma’s AP-101, a monoclonal antibody targeting misfolded SOD1, met its primary safety and tolerability end poi...
Expanding the Future of Pediatric Migraine Care With Novel Pathways: Patricia Pozo-Rosich, MD, PhD
WATCH TIME: 3 minutes "The migraine field is unique in that even without a clear biomarker, we’ve managed to build a growing therapeutic arsenal. With...
Identifying Gaps in Lennox-Gastaut Syndrome Care Across the Lifespan
WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors. Lennox-Gastaut syndrome (LGS) is a rare epilepsy syndrome that typically b...
Personalized Extended Interval Dosing Reduces John Cunningham Virus Seroconversion Rate for Natalizumab
In a recently published study of patients with relapsing-remitting multiple sclerosis (RRMS), data showed that the seroconversion rate for John Cunnin...
NeurologyLive® Friday 5 — September 5, 2025
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from ne...
The changing landscape of primary autoimmune neuropathies
van den Berg, B. et al. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469–482 (2014). Lehmann, H. C...
Episode 149: Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne
Episode 149 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming servi...
Investigational BAT4406F Performs in Phase 2/3 Study of NMOSD, Leading to Early Enrollment Termination
In a recent company announcement, Bio-Thera Solutions has decided to close patient enrollment for its pivotal phase 2/3 trial (NCT06044350) of BAT4406...
NeurologyLive® Brain Games: September 7, 2025
Collaborative Strategies to Enhance Care and Data Sharing in LGS
AP-101 Meets Primary End Point in Phase 2 Study of SOD1 ALS
Expanding the Future of Pediatric Migraine Care With Novel Pathways: Patricia Pozo-Rosich, MD, PhD
Identifying Gaps in Lennox-Gastaut Syndrome Care Across the Lifespan
Personalized Extended Interval Dosing Reduces John Cunningham Virus Seroconversion Rate for Natalizumab
NeurologyLive® Friday 5 — September 5, 2025
The changing landscape of primary autoimmune neuropathies
Episode 149: Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne
Investigational BAT4406F Performs in Phase 2/3 Study of NMOSD, Leading to Early Enrollment Termination
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago